Introduction
In adult life, pituitary growth hormone (GH) secretion is mainly controlled by the stimulatory action of growth hormone releasing hormone (GHRH) and by the inhibitory effect of somatostatin (SRIH). Besides that, other factors seem to be involved in the regulation of GH secretion. Noradrenaline, dopamine (DA) and serotonine have a stimulatory action on GH secretion. Activation of central nervous system (C. N. S.) cholinergic pathways enhances GH secretion and the administration of gabaergic compounds has a stimulatory effect on GH release. In rat, opioid peptides have been reported to stimulate GH secretion, and in man the administration of an analogue of metenkefaline (FK 33 -084) was effective in increasing serum GH concentrations [10, 18] . The regulation of GH secretion during fetal life or in the perinatal period has been less extensively studied. In the term fetus, cord blood GH concentrations are elevated. This condition has been attributed to an immaturity of the hypothalamic mechanisms controlling GH release [6] . This interpretation seems to be supported by studies describing a paradoxical response of GH following the administration of different substances such as glucose [6] , aminoacids [13] , L-dopa [5] , and thyrotropin releasing hormone (TRH) [15] . In contrast, the pattern of GH response to the administration of other compounds such as SRIH [16] , arginine [12] and insulin [3] , indicates that GH secretion is regulated by mechanisms similar to those present in the adult life.
In the present study we have evaluated the effect of the maternal administration of bromocriptine on fetal and maternal serum GH concentrations. In the adult, the administration of bromocriptine, a DA agonist drug, has been found to have a stimulatory effect on GH secretion [2] .
Materials and methods
Eighty-seven normal, term pregnant women were studied at parturition with their informed consent. During labor 46 women, randomly selected, were orally administered with 5 mg of bromocriptine, whereas 41 received a placebo. Records were kept detailing the time of bromocriptine or placebo ingestion and the time of parturition. Maternal and cord blood (CB) specimens were obtained at parturition time from all mothers and their neonates. Serum was separated by centrifugation from red cells and stored at -20 °C until assay. During labor and delivery no adverse effects were observed. The clinical course of neonates whose mothers were treated with bromocriptine was uneventful.
Serum GH concentration was measured in all MS and CB samples, except few whose volume was not sufficient.
All samples, diluted 1 : 4 in phosphate buffer, were measured in duplicate in the same assay and in random order employing materials obtained by Biodata (Milan, Italy). In this assay the cross reactivity with human Placental Lactogen (hPL) is 0.1%.
For statistical evaluation, GH results in MS obtained before bromocriptine and placebo ingestion were assigned to two groups: basal treated and basal control. GH results in MS specimens obtained at parturition were assigned to two groups: treated and control. Each of these two groups was subdivided into 7 subgroups according to the interval of time elapsed between bromocriptine or placebo ingestion and parturition time. GH results of neonates whose mothers were treated with bromocriptine were assigned to one group, treated, subdivided in 7 subgroups depending upon the interval of time between drug assumption and parturition time.
Similarly was done for GH concentrations of neonates whose mothers were treated with placebo.
Statistical analysis was conducted using Student's t test for unpaired samples and one way analysis of variance (ANOVA). All values are expressed as the mean + SE.
Results
Serum GH concentration in maternal serum: Before treatment, serum GH concentration in pregnant women receiving bromocriptine and placebo was 4.1 ± 0.1 ng/ml and 3.9 ± 0.1 ng/ml, respectively (t test, NS).
At parturition, in control subgroups serum GH concentration averaged between 3.6 and 4.7 ng/ ml. These values were not significantly different (ANOVA test) from those observed in mothers administered with bromocriptine. In these subjects, serum GH concentration fluctuated between 3.5 and 4.5 ng/ml (table I) .
Serum GH concentration in cord blood:
In CB samples of neonates whose mothers were treated with placebo, serum GH concentrations were not different (ANOVA test) from those measured in neonates whose mothers received bromocriptine (figure 1).
In both groups, control and treated, cord blood GH concentrations were significantly higher than the corresponding maternal values, p < 0.001 (t test).
Discussion
The participation of the dopaminergic pathways in the control of GH release has been clearly documented in man [18] . It is well known that DA agonist drug administration induces an increase of serum GH concentration [10] . In healthy adult subjects bromocriptine administration induces a rapid increase of GH secretion whereas in acromegalic patients significantly lowers serum GH concentrations [2] .
During the perinatal period the role of DA in the control of GH secretion has been poorly investigated. In the neonate, a paradoxical suppression of GH secretion has been observed after the administration of L-dopa [5] . In the ovine species, the administration of DA agonist drug induces a decrement of serum GH concentration both during adult [4] as well fetal and neonatal life [8] .
In fetal and neonatal monkey, as in adult, the administration of L-dopa induces an increase of serum GH concentrations [6] .
In the present study we have observed that the administration of bromocriptine to the mother does not induce any change of fetal serum GH concentrations. The lack of any effect of bromocriptine administration on fetal GH secretion does not seem to be related nor to an absent transfer of the drug through the placenta neither to an insufficient dose since we have observed that in newborns whose mothers received bromocriptine cord blood prolactin (PRL) concentrations were significantly lower than in newborns of control mothers [17] . Long term treatment with bromocriptine of an acromegalic patient througout pregnancy did not induce any change of fetal serum GH concentrations [1] . These findings are in agreement with the observation that maternal administration of metoclopramide, a dopaminergic receptor blocking drug, did not modify cord blood GH concentrations (RoTi, unpublished data).
Thus it is likely that the absent action of bromocriptine on fetal GH secretion might be due to a lack of activation of DA receptors at the hypothalamic and/or pituitary level.
The administration of bromocriptine, as well, did not induce any change in maternal serum GH concentrations. This finding has been previously reported in an acromegalic pregnant woman chronically treated with bromocriptine [1] , These results are in agreement with a previous observation from our laboratory [11] reporting that the administration of metoclopramide to parturient women did not induce any change of serum GH concentrations.
During late pregnancy, it has been reported an absent or blunted serum GH surge following secretory stimuli such as insulin induced hypoglycemia [9] and arginine infusion [21] . The increased serum concentrations of hPL [7] , corticosteroids [4] and progestins [20] have been indicated as possible hormonal factors responsible for the absent GH response to insulin induced hypoglycemia.
Finally the hyperprolactinemic state both in maternal and fetal compartments might explain the absent GH response to bromocriptine. Recently it has been reported that in hyperprolactinemic women with pituitary microadenoma the administration of levo-DOPA and bromocriptine failed to stimulate GH secretion. This finding has been related to an impaired hypothalamic GHRH secretion or to decreased pituitary sensitivity to GHRH since L-Dopa and bromocriptine seem to act on GH release via GHRH [19] .
In conclusion the present study suggests that in contrast to adult normal subjects bromocriptine administration does not enhance fetal and maternal serum GH levels.
Summary
To investigate the role of dopaminergic pathways on the control of growth hormone (GH) secretion, bromocriptine (BMC), a dopamine agonist drug, was orally administered at the dose of 5 mg to 46 pregnant women during labor whereas 41 received placebo. Maternal blood was obtained before drug administration and at delivery. Cord blood was obtained at delivery. Following the interval of time elapsed between BMC or placebo ingestion and parturition, maternal and cord blood samKeywords: Bromocriptine, fetal growth hormone.
pies were divided in 7 groups for statistical analysis. Cord blood GH resulted significantly higher than the corresponding maternal value (p < 0.001). No significant change in GH values was observed nor in samples of mothers treated with BMC compared to mothers treated with placebo neither in cord blood samples of the corresponding neonates. These findings indicate that BMC administration does not modify GH secretion in the term fetus. Afin d'explorer le röle des voies dopaminergiques sur le controle de la secretion de l'hormone de croissance (GH), on a donne per os de la bromocriptine (BMC), medicament agoniste de la dopamine, a la dose de 5 mg, ä 46 femmes enceintes, pendant le travail, tandis que 41 femmes prenaient un placebo. Du sang maternel a ete preleve avant la prise medicamenteuse et a 1'accouchement. On a preleve du sang au cordon lors de Faccouchement. En fonction de l'intervalle de temps qui s'est ecoule entre la prise de BMC ou du placebo et FaccouMots-cles: Bromocriptine, hormone de croissance foetale (GH). chement, les prelevements sanguins maternels et du cordon ont ete divises en 7 groupes pour 1'analyse statistique. Les resultats montrent que les valeurs de GH au sang du cordon etaient significativement plus elevees que les valeurs maternelles correspondantes (p < 0,001). On n'a pas observe de modifications significatives des valeurs de GH ni dans les prelevements de meres traitees par BMC en comparaison avec les meres avec placebo ni dans les prelevements au sang du cordon chez les nourrissons correspondants. Ces resultats indiquent que administration de BMC ne modifie pas la secretion de GH chez le foetus a terme.
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